Gut Bacterial ClpB Protein Drives Anorexia in Mice, and Immunization Against It Offers Protection
Lowering a gut bacterial protein that mimics an appetite-suppressing hormone protected mice from anorexia-like weight loss, hinting at a possible new biotherapy.
Summary
Anorexia nervosa has no known cause, and treatment options are limited. This mouse study examined ClpB, a protein made by Enterobacteriaceae gut bacteria that mimics α-MSH, a hormone that suppresses appetite. Researchers used the activity-based anorexia (ABA) model, in which mice lose weight, eat less and become hyperactive. When immunization produced antibodies that lowered ClpB, mice kept more lean mass, ate more and showed less food-anticipatory activity. When antibody production came with a rise in ClpB, the anorexia got worse. Antibodies also blocked ClpB and α-MSH from activating the melanocortin 4 receptor in laboratory tests. Fecal microbiota diversity and energy content did not change. The findings point to ClpB, and the immune system's control of it, as a contributor to anorexia in this model. They suggest that neutralizing ClpB by immunization could eventually become a therapy, though this is preclinical work.
Detailed Summary
Anorexia nervosa is a serious psychiatric illness with unknown causes and few effective treatments. Identifying biological contributors, including those from the gut microbiome, could open new therapeutic options. This matters for clinicians and for readers interested in how gut bacteria shape appetite and behavior.
The researchers studied caseinolytic protease B (ClpB), a protein produced by Enterobacteriaceae. ClpB was previously identified as an antigen mimetic of α-melanocyte-stimulating hormone (α-MSH), an appetite-suppressing neuropeptide. They tested its role in activity-based anorexia (ABA), a rodent model of anorexia nervosa, in two series of ClpB immunization experiments.
Mice whose ClpB was lowered by antibodies were protected from ABA. They preserved lean mass, increased food intake and showed less feeding anticipatory activity. When antibody production was accompanied by a rise in ClpB, ABA worsened. Experiments in ClpB-tolerized mice, and tests showing that IgG inhibited ClpB- and α-MSH-induced activation of the melanocortin 4 receptor, supported a key protective role for anti-ClpB IgG. Immunization changed clpB DNA abundance in ABA mice but did not alter fecal microbiota diversity or energy content.
The results support a role for Enterobacterial ClpB, and for immune control of it, in host anorexia. They provide a rationale for ClpB immunoneutralization as a possible biotherapy for anorexia nervosa.
Caveats: this analysis is based only on the abstract. ABA is an animal model that cannot capture the psychiatric complexity of human anorexia nervosa. Human efficacy and safety of ClpB-targeted immunization remain untested, and full methods, sample sizes and effect sizes were not available for review.
Key Findings
- Antibody-mediated reduction of ClpB protected mice from activity-based anorexia, preserving lean mass and raising food intake.
- Immunization lowered feeding anticipatory activity in ABA mice with reduced ClpB.
- Antibody production accompanied by increased ClpB aggravated anorexia in the ABA model.
- Anti-ClpB IgG inhibited ClpB- and α-MSH-induced melanocortin 4 receptor activation in vitro.
- Immunization altered clpB DNA abundance without changing fecal microbiota diversity or energy content.
Methodology
Researchers ran two series of ClpB immunization experiments in mice using the activity-based anorexia model. They also used ClpB-tolerized mice and receptor activation assays testing IgG inhibition of ClpB and α-MSH at the melanocortin 4 receptor, and assessed clpB DNA abundance, fecal microbiota diversity and fecal energy content.
Study Limitations
Findings come from a mouse model that only partly reflects human anorexia nervosa, and this summary relies on the abstract alone, without sample sizes or effect sizes. Safety and efficacy of manipulating ClpB or immune responses in humans are unknown, and causality in patients remains unproven.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: